Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce today that Health Canada has authorized Vabysmo® ...

Atrial fibrillation (AF) is the most common abnormal heart rhythm affecting 6 million people in the USA and can cause strokes and heart failure. Conventional treatments are successful but may need to ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...

A mathematical model suggests that existing HPA-targeting drugs failed in clinical trials for mood disorders because the ...

From an immunologic point of view, condom therapy, although it may work, is illogical. Although the antibody activity declined from 1:256 to 1:8 after 7 months of condom therapy, antibody titer ...

Antibody-Drug Conjugates (ADCs ... as well as to determine the appropriate therapeutic dose via dose escalation. Mechanism of ABBV-969. Image Credit: ACROBiosystems In addition, bispecific ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

Merus is a buy with Bizengri approval for NRG1+ cancers, Petosemtamab's potential, and partnership with BHVN for oncology ...